PDCD1 and neoplasm: A recently published meta-analysis assessed the diagnostic accuracy of PD-L1 immunohistochemistry, tumor mutational burden (TMB), gene expression profiling (GEP), and multiplex immunohistochemistry/immunofluorescence (mIHC/IF) in predicting response to anti-PD-1/PD-L1 therapy, and mIHC/IF demonstrated higher positive predictive values (0.63) and positive likelihood ratios (2.86) than the other approaches (16).